5910-12-3

Usage

Uses

Used in Pharmaceutical Research and Development:
3-BROMO-PYRAZOLO[1,5-A]PYRIDINE is used as a key intermediate in the synthesis of biologically active molecules for drug discovery. Its unique structure allows for the development of new pharmaceutical agents with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 3-BROMO-PYRAZOLO[1,5-A]PYRIDINE is utilized as a building block for the preparation of various functionalized heterocyclic compounds. These compounds can be further modified to create a wide range of chemical entities with diverse properties and applications.
Used in Materials Science:
3-BROMO-PYRAZOLO[1,5-A]PYRIDINE may have interesting properties and potential uses in materials science. Its unique structure and functional groups can contribute to the development of new materials with specific characteristics, such as improved stability, reactivity, or selectivity, making it a valuable compound for further study and exploration in this field.

InChI:InChI=1/C7H5BrN2/c8-6-5-9-10-4-2-1-3-7(6)10/h1-5H

Upstream product

• 16205-44-0 Pyrazolo<1,5-a>pyridin-3-carbonsaeureethylester 
• 16205-46-2 pyrazolo[1,5-a]pyridine-3-carboxylic acid 

Downstream Products

• 1207557-48-9 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)pyrazolo[1,5-a]pyridine 

Relevant academic research and scientific papers

2-pyridine substituted urea structural small molecule compounds as well as synthesis and application thereof

The invention relates to 2-pyridine substituted urea structural small molecule compounds as well as synthesis and application thereof. Specifically, the invention discloses the compounds represented by a formula (I) shown in the specification, enantiomers, diastereomers, racemates or a mixture of the compounds, or a pharmaceutically acceptable salt, hydrate and solvate of the compounds, a preparation method of the above materials, and applications of the above materials in preparation of an ASK1 small molecule inhibitor, or medicines for preventing and/or treating diseases related to ASK1, especially liver diseases, lung diseases, cardiovascular diseases, kidney diseases and metabolic diseases.

Azacycle diketone compound and preparation method thereof (by machine translation)

The invention provides a azacyclodiketone compound which is characterized by being a compound represented by the following structure. The compound has inhibitory activity on cap-dependent endonuclease. (by machine translation)

PYRAZOLE DERIVATIVES AS JAK INHIBITORS

New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).